Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.
12 October 2026 in Biotechnology and Bioengineering
Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate the hepatic microenvironment, even when improved by adding additional cell types and extracellular matrix (ECM). These models do not address all necessary key components to mimic in vivo conditions, particularly multicellularity, specific ECM, and proper biophysical and biochemical parameters. Organoids, 3D‐bioprinted constructs, and liver‐on‐chip platforms establish physiologically relevant models by improving cell–cell and cell–matrix interactions and multicellular architecture. For a comprehensive understanding of the liver's interconnections with related tissues and organs, a multi‐organ‐on‐chip is a useful platform for more systemic studies. Also, other interdisciplinary approaches, particularly omics and artificial intelligence (AI), can enhance the accuracy of experimental and pre‐clinical data achieved by such advanced in vitro liver platforms. This review highlights developing platforms for integrated approaches in experimental liver studies to enable researchers to have a holistic view of the liver in physiologic and pathologic conditions.